Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2026 07:00 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

Eledon Presents Long-Term Phase 2 BESTOW Results at ATC Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart
June 08, 2026 07:00 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
June 05, 2026 19:32 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including...
June 04, 2026 16:31 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at ADA
May 20, 2026 06:40 ET | Source: Research and Markets

Insulin Delivery Devices Market Analysis and Growth Forecasts Report 2026-2033 - Uncover New Revenue Streams and Guide Strategic Business Decisions

Dublin, May 20, 2026 (GLOBE NEWSWIRE) -- The "Insulin Delivery Devices Market Size, Share & Trends Analysis Report by Product, End Use, Region, and Growth Forecasts, 2026-2033" report has been...
May 13, 2026 16:05 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 12, 2026 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C....
May 05, 2026 17:50 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced...
April 27, 2026 17:37 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence...
April 17, 2026 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further...